| Mar 26 | Dec 24 | Dec 23 | Dec 22 | Jun 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 50.74M | $ 32.18M | $ 16.54M | £ 4.48M | £ 1.52M |
| Gross Profit | $ 22.38M | $ 13.22M | $ 5.09M | £ 2.00M | £ -1.67M |
| Operating Income | $ -10.30M | $ -22.87M | $ -31.33M | £ -26.39M | £ -20.41M |
| EBITDA | $ -9.16M | $ -21.26M | $ -38.28M | £ -46.07M | £ -17.69M |
| Net Income | $ -18.03M | $ -26.61M | $ -33.29M | £ -40.44M | £ -19.34M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 11.63M | $ 7.02M | $ 17.63M | £ 2.82M | £ 12.12M |
| Total Assets | $ 65.24M | $ 57.42M | $ 48.80M | £ 22.07M | £ 44.41M |
| Total Debt | $ 30.15M | $ 26.34M | $ 25.80M | £ 6.10M | £ 156.00K |
| Net Debt | $ 18.52M | $ 19.33M | $ 8.17M | £ 3.28M | £ -11.96M |
| Total Liabilities | $ 80.32M | $ 58.74M | $ 33.77M | £ 16.65M | £ 3.38M |
| Stockholders' Equity | $ -15.08M | $ -1.32M | $ 11.79M | £ 5.43M | £ 40.69M |
| Cash Flow | |||||
| Free Cash Flow | $ -8.83M | $ -8.80M | $ -50.65M | £ -20.14M | £ -18.80M |
| Operating Cash Flow | $ -8.81M | $ -8.77M | $ -46.93M | £ -18.25M | £ -16.74M |
| Investing Cash Flow | $ -306.29K | $ -2.37M | $ -3.07M | £ -1.70M | £ -2.05M |
| Financing Cash Flow | $ 13.75M | $ 5.26M | $ 62.77M | £ 7.71M | £ 27.58M |
Shield Therapeutics PLC (DE:1JS)
FRANKFURT:1JS
